acquisition

J&J Vision Announces Acquisition of Sightbox, an Online CL Subscription Service

JACKSONVILLE, Fla.—Johnson Johnson Vision has acquired Sightbox Inc., an online, membership-based subscription service for contact lens wearers in the U.S., according to a JJ Vision announcement earlier this week. The terms of the deal were not disclosed. The acquisition will help more patients connect with ECPs through a member-based contact lens subscription service, JJ Vision said in its announcement. Sightbox also addresses “a growing consumer preference for more convenient access to eye health services and products,” the announcement noted. Sightbox will become part of Johnson Johnson Vision, but will operate as a separate business and will continue to provide contact…


Johnson & Johnson Vision Completes Acquisition of Device Manufacturer TearScience

SANTA ANA, Calif.—Johnson Johnson Vision has completed its previously announced acquisition of TearScience Inc., a medical device manufacturer that focuses on evaluating meibomian gland health and treating Meibomian Gland Dysfunction (MGD), the leading cause of dry eye disease. In an announcement earlier this week, JJ Vision said the transaction represents another step in its strategy to become “a broad-based, global leader in eye health and further expands the company’s leading eye health portfolio.” In addition, JJ Vision noted that the acquisition marks its expansion into dry eye medical device technology and provides “a complementary eye health solution to address an…


ForSight VISION4, Inc. Announces Acquisition by Roche

MENLO PARK, Calif.—ForSight VISION4, a privately held biotechnology company innovating drug delivery for treatment of retinal diseases, announced that it has been acquired by Roche Holdings Inc. (OTCQX:RHHBY) The company is the fourth venture created by the Menlo Park incubator, ForSight Labs, LLC, and was funded entirely by two of the leading venture capital firms in Silicon Valley, Morgenthaler Ventures and Versant Ventures. The acquisition expands Roche’s exclusive access to the ForSight VISION4 PDS technology for long acting delivery of therapeutics to the eye. In 2010, ForSight VISION4, Inc. announced a collaboration and license agreement with Genentech, a member of…


Sun Pharma Completes Acquisition of Ocular Technologies Sarl

NEW DELHI—Sun Pharmaceutical Industries announced that it has completed the acquisition of U.S.-based eyecare specialist Ocular Technologies Sarl, a portfolio company of Auven Therapeutics. As VMail previously reported, Sun Pharma was set to pay Auven $40 million upfront, plus contingent development milestones and sales milestones as well as tiered royalty on Seciera sales, which is currently in Phase-3 confirmatory clinical trials. “All the necessary formalities for closure of the said transaction have been concluded and the company has successfully completed the acquisition of Ocular Technologies Sarl, on December 15, 2016,” Sun Pharmaceutical Industries said in a BSE filing.


No Picture

Sun Pharma Completes Acquisition of Ocular Technologies Sarl

NEW DELHI—Sun Pharmaceutical Industries announced that it has completed the acquisition of U.S.-based eyecare specialist Ocular Technologies Sarl, a portfolio company of Auven Therapeutics. As VMail previously reported, Sun Pharma was set to pay Auven $40 million upfront, plus contingent development milestones and sales milestones as well as tiered royalty on Seciera sales, which is currently in Phase-3 confirmatory clinical trials. “All the necessary formalities for closure of the said transaction have been concluded and the company has successfully completed the acquisition of Ocular Technologies Sarl, on December 15, 2016,” Sun Pharmaceutical Industries said in a BSE filing.